早期经鼻高流量氧疗与标准氧疗对急性低氧性呼吸衰竭住院儿童住院时间的影响:PARIS-2随机临床试验
PARIS-2多中心随机临床试验在澳大利亚和新西兰14家医院纳入1567例1至4岁因急性低氧性呼吸衰竭住院的儿童,1:1随机分配至经鼻高流量氧疗组(n=753)或标准氧疗组(n=764)。主要终点住院时间在高流量组显著更长:中位1.77天(IQR 1.03-2.80)vs 标准氧疗组1.50天(IQR 0.85-2.44),校正风险比0.83(95%CI 0.75-0.92),P<.001。氧疗时间中位1.07天 vs 0.75天(校正风险比0.78,95%CI 0.70-0.86);ICU入住94例(12.5%)vs 53例(6.9%)(校正比值比1.93,95%CI 1.35-2.75)。9项预设次要结局中4项无显著差异;仅1例死亡,发生于高流量组。结论认为,在1至4岁急性低氧性呼吸衰竭儿童中,经鼻高流量氧疗作为初始主要治疗未显著缩短住院时间。
要点
- 1至4岁急性低氧性呼吸衰竭住院儿童中,早期经鼻高流量氧疗组住院时间中位1.77天 vs 标准氧疗组1.50天,校正风险比0.83(95%CI 0.75-0.92),P<.001
- 高流量组氧疗时间中位1.07天 vs 标准氧疗组0.75天,校正风险比0.78(95%CI 0.70-0.86)
- 高流量组ICU入住94例(12.5%)vs 标准氧疗组53例(6.9%),校正比值比1.93(95%CI 1.35-2.75)
- 9项预设次要结局中4项无显著差异;仅1例死亡,发生于高流量组
- 作者结论:经鼻高流量氧疗作为初始主要治疗未显著缩短住院时间
适用人群与场景
- 年龄1至4岁、因急性低氧性呼吸衰竭需住院的儿童;排除毛细支气管炎(原文背景指出毛细支气管炎婴儿已有证据,本研究针对无毛细支气管炎的1至4岁儿童)
- 研究在澳大利亚和新西兰14家大都市和三级医院开展,随机时间为2017年12月18日至2020年3月18日,末例随访完成于2020年3月22日
处置流程与药物剂量
- 入组儿童1:1随机分配至经鼻高流量氧疗(n=753)或标准氧疗(n=764);氧疗类型无法设盲,但研究者对结局数据保持盲态直至数据锁定
研究设计与关键结果
- 多中心随机临床试验,纳入1567例1至4岁急性低氧性呼吸衰竭住院儿童,随机分配至高流量氧疗组(n=753)或标准氧疗组(n=764);主要分析纳入1517例(97%),中位年龄1.9岁(IQR 1.4-3.0岁),女性732例(46.7%),全部儿童完成试验
- 主要终点住院时间:高流量组中位1.77天(IQR 1.03-2.80)vs 标准氧疗组1.50天(IQR 0.85-2.44),校正风险比0.83(95%CI 0.75-0.92),P<.001,高流量组住院时间显著更长
- 氧疗时间:高流量组中位1.07天(IQR 0.50-2.06)vs 标准氧疗组0.75天(IQR 0.35-1.61),校正风险比0.78(95%CI 0.70-0.86)
- ICU入住:高流量组94例(12.5%)vs 标准氧疗组53例(6.9%),校正比值比1.93(95%CI 1.35-2.75)
- 9项预设次要结局中4项无显著差异;仅1例死亡,发生于高流量组
证据类型、等级与局限
- 证据类型:多中心随机临床试验(RCT)
- 局限:原文未报告局限性
对床旁实践的改变
- 在1至4岁无毛细支气管炎的急性低氧性呼吸衰竭住院儿童中,将经鼻高流量氧疗作为初始主要治疗未显著缩短住院时间,且住院时间、氧疗时间和ICU入住率均高于标准氧疗组;作者结论认为经鼻高流量氧疗作为初始主要治疗未显著缩短住院时间
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Nasal high-flow oxygen therapy in infants with bronchiolitis and hypoxia has been shown to reduce the requirement to escalate care. The efficacy of high-flow oxygen therapy in children aged 1 to 4 years with acute hypoxemic respiratory failure without bronchiolitis is unknown.
OBJECTIVE: To determine the effect of early high-flow oxygen therapy vs standard oxygen therapy in children with acute hypoxemic respiratory failure.
DESIGN, SETTING, AND PARTICIPANTS: A multicenter, randomized clinical trial was conducted at 14 metropolitan and tertiary hospitals in Australia and New Zealand, including 1567 children aged 1 to 4 years (randomized between December 18, 2017, and March 18, 2020) requiring hospital admission for acute hypoxemic respiratory failure. The last participant follow-up was completed on March 22, 2020.
INTERVENTIONS: Enrolled children were randomly allocated 1:1 to high-flow oxygen therapy (n = 753) or standard oxygen therapy (n = 764). The type of oxygen therapy could not be masked, but the investigators remained blinded until the outcome data were locked.
MAIN OUTCOMES AND MEASURES: The primary outcome was length of hospital stay with the hypothesis that high-flow oxygen therapy reduces length of stay. There were 9 secondary outcomes, including length of oxygen therapy and admission to the intensive care unit. Children were analyzed according to their randomization group.
RESULTS: Of the 1567 children who were randomized, 1517 (97%) were included in the primary analysis (median age, 1.9 years [IQR, 1.4-3.0 years]; 732 [46.7%] were female) and all children completed the trial. The length of hospital stay was significantly longer in the high-flow oxygen group with a median of 1.77 days (IQR, 1.03-2.80 days) vs 1.50 days (IQR, 0.85-2.44 days) in the standard oxygen group (adjusted hazard ratio, 0.83 [95% CI, 0.75-0.92]; P < .001). Of the 9 prespecified secondary outcomes, 4 showed no significant difference. The median length of oxygen therapy was 1.07 days (IQR, 0.50-2.06 days) in the high-flow oxygen group vs 0.75 days (IQR, 0.35-1.61 days) in the standard oxygen therapy group (adjusted hazard ratio, 0.78 [95% CI, 0.70-0.86]). In the high-flow oxygen group, there were 94 admissions (12.5%) to the intensive care unit compared with 53 admissions (6.9%) in the standard oxygen group (adjusted odds ratio, 1.93 [95% CI, 1.35-2.75]). There was only 1 death and it occurred in the high-flow oxygen group.
CONCLUSIONS AND RELEVANCE: Nasal high-flow oxygen used as the initial primary therapy in children aged 1 to 4 years with acute hypoxemic respiratory failure did not significantly reduce the length of hospital stay compared with standard oxygen therapy.
TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12618000210279.
参考来源
- Franklin D, Babl FE, George S, et al. Effect of Early High-Flow Nasal Oxygen vs Standard Oxygen Therapy on Length of Hospital Stay in Hospitalized Children With Acute Hypoxemic Respiratory Failure: The PARIS-2 Randomized Clinical Trial. JAMA. 2023. PMID: 36648469. doi:10.1001/jama.2022.21805
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。